
CLAIMS

1. A solid pharmaceutical composition, comprising a compound of formula **I**, a diluent, a binder, a disintegrant, and a lubricant,



I

wherein

the diluent is selected from the group consisting of microcrystalline cellulose, mannitol, lactose, ~~sucrose, starch,~~ pregelatinized starch, ~~dextrin,~~ and a mixture thereof;

the disintegrant is selected from the group consisting of sodium carboxymethyl starch, ~~dry starch, microcrystalline cellulose, hydroxyethyl methylcellulose, carboxymethylcellulose sodium, carboxymethylcellulose calcium,~~ croscarmellose sodium, ~~low-substituted hydroxypropyl methylcellulose or crospovidone, sodium dodecyl sulfate or magnesium dodecyl sulfate,~~ and a mixture thereof;

the binder is selected from the group consisting of hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, ethylcellulose, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, ~~gelatin,~~ polyvinylpyrrolidone, ~~partially hydrolyzed starch, pregelatinized starch, glucose, polyethylene glycol, polyvinyl alcohol,~~ and a mixture thereof;

the lubricant is selected from the group consisting of magnesium stearate, colloidal silicon dioxide, ~~talc, polyethylene glycol 4000, polyethylene glycol 6000, stearic acid, sodium stearyl fumarate,~~ sodium dodecyl sulfate, and a mixture thereof;

the solid pharmaceutical composition is prepared by a direct compression method.

2. The solid pharmaceutical composition according to claim 1, wherein,

the solid pharmaceutical composition is a pharmaceutical composition in unit dose, and the mass of the compound of formula **I** in the composition per unit dose is 0.01 mg-10 mg; or

the amount of the compound of formula **I** is selected from 0.01%-10% wt.

3. The solid pharmaceutical composition according to claim 1, wherein,

the diluent is selected from the group consisting of ~~microcrystalline cellulose, mannitol, lactose, pregelatinized starch, and a mixture thereof; more preferably,~~ microcrystalline

cellulose, pregelatinized starch, and a mixture thereof.

4. The solid pharmaceutical composition according to claim 1, wherein,
the amount of the diluent is selected from 50% wt or more.

5. The solid pharmaceutical composition according to claim 4, wherein,
the diluent comprises microcrystalline cellulose, and the amount of the microcrystalline cellulose is selected from 30%-90% wt; or
the diluent comprises pregelatinized starch, and the amount of the pregelatinized starch is selected from 5%-35% wt; or
the diluent is microcrystalline cellulose and pregelatinized starch; preferably, 30%-90% wt of microcrystalline cellulose and 5%-35% wt of pregelatinized starch, and the amount of the diluent is 50% wt or more.

6. The solid pharmaceutical composition according to claim 1, wherein,
the disintegrant is ~~selected from the group consisting of sodium carboxymethyl starch, croscarmellose sodium, and a mixture thereof; more preferably,~~ sodium carboxymethyl starch.

7. The solid pharmaceutical composition according to claim 6, wherein,
the amount of the disintegrant is selected from 1.0%-7.0% wt; or
the disintegrant is sodium carboxymethyl starch, and the amount of the sodium carboxymethyl starch is selected from 1.0%-7.0% wt.

8. The solid pharmaceutical composition according to claim 1, wherein,
the binder is ~~selected from the group consisting of hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, ethylcellulose, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), polyvinylpyrrolidone, and a mixture thereof; more preferably,~~ hydroxypropyl methylcellulose.

9. The solid pharmaceutical composition according to claim 8, wherein,
the amount of the binder is selected from 0.1%-5% wt; or
the binder is hydroxypropyl methylcellulose, and the amount of the hydroxypropyl methylcellulose is selected from 0.1%-5% wt.

10. The solid pharmaceutical composition according to claim 1, wherein,
the lubricant is selected from the group consisting of ~~magnesium stearate, colloidal silicon dioxide, sodium dodecyl sulfate, and a mixture thereof; more preferably,~~ magnesium stearate, colloidal silicon dioxide, and a mixture thereof.

11. The solid pharmaceutical composition according to claim 10, wherein,
the amount of the lubricant is selected from 0.1%-5% wt; or
the lubricant comprises colloidal silicon dioxide, and the amount of the colloidal silicon dioxide is selected from 0.05%-3.0% wt; or
the lubricant comprises magnesium stearate, and the amount of the magnesium stearate is selected from 0.05%-3.0% wt; or
the lubricant is selected from the group consisting of colloidal silicon dioxide and magnesium stearate; preferably, 0.05%-3.0% wt of colloidal silicon dioxide and 0.05%-3.0% wt of magnesium stearate, and the amount of the lubricant is selected from 0.1%-5% wt.

12. The solid pharmaceutical composition according to any one of claims 1-11, wherein the solid pharmaceutical composition comprises:
0.02%-8.0% wt of the compound of formula **I**;
50% wt or more of microcrystalline cellulose, mannitol, lactose, pregelatinized starch, or a mixture thereof;
1.0%-7.0% wt of sodium carboxymethyl starch, croscarmellose sodium, or a mixture thereof;
0.1%-5% wt of hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, ethylcellulose, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, polyvinylpyrrolidone, or a mixture thereof; and
0.1%-5% wt of magnesium stearate, colloidal silicon dioxide, sodium dodecyl sulfate, or a mixture thereof.

13. The solid pharmaceutical composition according to any one of claims 1-12, wherein the solid pharmaceutical composition has at least one of the following characteristics:
the bulk density is less than or equal to 0.50 g/mL, preferably, 0.30 g/mL-0.50 g/mL;
the tap density is less than or equal to 0.65 g/mL, preferably, 0.50 g/mL-0.65 g/mL;
the Hausner ratio is 1.31-1.40;
particles, with an amount of more than or equal to 50%, preferably, 50%-80%, have a size of less than 75 μm.

14. The solid pharmaceutical composition according to any one of claims 1-13, wherein,
the dosage form of the solid pharmaceutical composition may be selected from a powder, a granule, a tablet, a capsule, a pill, a pellet, a dispersion and an inhalable powder, preferably, a tablet.

~~15. The solid pharmaceutical composition according to any one of claims 1-14, wherein,~~
~~the solid pharmaceutical composition is prepared by a direct compression method.~~

~~16~~15. A method for preparing the solid pharmaceutical composition of the compound of formula **I** according to any one of claims 1-~~15~~14, comprising the direct compression method.

~~17~~16. A method for preparing the solid pharmaceutical composition of the compound of formula **I** according to any one of claims 1-~~15~~14, comprising:
1) mixing the compound of formula I with part or all of the diluent and, optionally present, at least one of the binder, the disintegrant and the lubricant;
2) mixing the resulting mixture obtained in step 1) with the rest of the diluent and at least one of the rest of the binder, the disintegrant and the lubricant;
optionally, 3) mixing the resulting mixture obtained in step 2) with the rest of the excipients; and
4) tableting the resulting mixture obtained in step 2) or step 3).

~~18~~17. The method according to claim ~~16~~15 or ~~17~~16, wherein,
the method comprises the following steps: 1) preparing the compound of formula **I**, the diluent, the disintegrant, the binder and the lubricant into a mixture; and 2) tableting.

~~19~~18. The method according to any one of claims ~~16~~15-~~18~~17, wherein,
the mixture comprising the compound of formula I and the diluent is not subjected to milling.

~~20~~19. Use of the solid pharmaceutical composition of the compound of formula **I** according to any one of claims 1-~~15~~14 for the manufacture of a medicament for the treatment or prevention of a disease associated with TLR7~~;~~.

20. The use according to claim 19~~preferably~~, wherein the disease associated with TLR7 is

selected from a viral infectious disease; more preferably, the viral infectious disease is selected from the group consisting of hepatitis B and hepatitis C.